New York State Common Retirement Fund Sells 15,400 Shares of Eli Lilly and Company (LLY)
New York State Common Retirement Fund lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,128,631 shares of the company’s stock after selling 15,400 shares during the period. New York State Common Retirement Fund owned about 0.28% of Eli Lilly and worth $267,623,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of LLY. BlackRock Inc. increased its holdings in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares in the last quarter. Dodge & Cox increased its holdings in Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after acquiring an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after acquiring an additional 2,714,505 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares in the last quarter. Hedge funds and other institutional investors own 76.42% of the company’s stock.
In related news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 651,088 shares of company stock valued at $56,439,586. 0.20% of the stock is currently owned by insiders.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the firm posted $0.88 earnings per share. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.60%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
Several equities research analysts recently issued reports on LLY shares. Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Cowen reissued a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a report on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a report on Monday, September 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $90.25.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-sells-15400-shares-of-eli-lilly-and-company-lly/1769657.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.